Bill > S775

This bill, the Increasing Transparency in Generic Drug Applications Act, aims to provide more transparency in the review process for generic drug applications. The key provisions include: 1. Requiring the FDA to inform applicants if a proposed generic drug is qualitatively and quantitatively the same as the referenced brand-name drug, and if not, to identify the specific ingredients that cause the differences. 2. Prohibiting the FDA from changing a determination that a generic drug is qualitatively and quantitatively the same as the referenced drug, unless the brand-name drug's formulation has changed or the FDA identifies an error in the prior determination. 3. Requiring the FDA to issue guidance within one year on how it will determine if a generic drug is qualitatively and quantitatively the same as the referenced drug, including for ingredients like pH adjusters. 4. Stating that the new transparency requirements apply starting on the date of the bill's enactment, regardless of when the guidance is finalized. The goal of this bill is to enhance the information available to generic drug applicants and provide more clarity in the FDA's review process for determining therapeutic equivalence between generic and brand-name drugs.